Literature DB >> 12146799

The clinical course of experimental autoimmune encephalomyelitis is associated with a profound and sustained transcriptional activation of the genes encoding toll-like receptor 2 and CD14 in the mouse CNS.

Hakima Zekki1, Douglas L Feinstein, Serge Rivest.   

Abstract

Experimental autoimmune encephalomyelitis (EAE) is an autoimmune demyelinating disease commonly used to model the pathogenetic mechanisms involved in multiple sclerosis (MS). In this study, we examined the effects of immunization with the myelin oligodendrocyte glycoprotein MOG(35-55) on the expression of molecules of the innate immune system, namely toll-like receptor 2 (TLR2) and CD14. Expression of the mRNA encoding TLR2 increased in the choroid plexus, the leptomeninges and within few isolated cells in the CNS parenchyma 4 to 8 days after immunization with MOG. At day 10, the signal spread across the meninges, few perivascular regions and over isolated groups of parenchymal cells. Three weeks after the MOG treatment, at which time animals showed severe clinical symptoms, a robust expression of both TLR2 and CD14 transcripts occurred in barrier-associated structures, as well as parenchymal elements of the spinal cord, and within numerous regions of the brain including, the medulla, cerebellum and the cortex. Dual labeling provided the anatomical evidence that microglia/macrophages were positive for TLR2 in the brain of EAE mice. The regions that exhibited chronic expression of TLR2 and CD14 were also associated with an increase in NF-kappaB activity and transcriptional activation of genes encoding numerous proinflammatory molecules. The present data provide evidence that receptors of the pathogen-associated molecular patterns are strongly induced in the CNS of EAE mice, further reinforcing the concept that the innate immune system plays a determinant role in this autoimmune demyelinating disease.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12146799     DOI: 10.1111/j.1750-3639.2002.tb00445.x

Source DB:  PubMed          Journal:  Brain Pathol        ISSN: 1015-6305            Impact factor:   6.508


  33 in total

Review 1.  Mycobacteria-induced suppression of autoimmunity in the central nervous system.

Authors:  JangEun Lee; Matyas Sandor; Erika Heninger; Zsuzsanna Fabry
Journal:  J Neuroimmune Pharmacol       Date:  2010-03-24       Impact factor: 4.147

2.  Toll-like receptor 2 (TLR2) is pivotal for recognition of S. aureus peptidoglycan but not intact bacteria by microglia.

Authors:  Tammy Kielian; Nilufer Esen; Edward D Bearden
Journal:  Glia       Date:  2005-03       Impact factor: 7.452

Review 3.  Enhanced prospects for drug delivery and brain targeting by the choroid plexus-CSF route.

Authors:  Conrad E Johanson; John A Duncan; Edward G Stopa; Andrew Baird
Journal:  Pharm Res       Date:  2005-07-22       Impact factor: 4.200

Review 4.  Toll-like receptors in defense and damage of the central nervous system.

Authors:  Rajagopal N Aravalli; Phillip K Peterson; James R Lokensgard
Journal:  J Neuroimmune Pharmacol       Date:  2007-04-03       Impact factor: 4.147

5.  Altered innate immune response of plasmacytoid dendritic cells in multiple sclerosis.

Authors:  A Bayas; M Stasiolek; N Kruse; K V Toyka; K Selmaj; R Gold
Journal:  Clin Exp Immunol       Date:  2009-09       Impact factor: 4.330

6.  Differential monocyte responses to TLR ligands in children with autism spectrum disorders.

Authors:  Amanda M Enstrom; Charity E Onore; Judy A Van de Water; Paul Ashwood
Journal:  Brain Behav Immun       Date:  2009-08-08       Impact factor: 7.217

Review 7.  Glial toll-like receptor signaling in central nervous system infection and autoimmunity.

Authors:  Pamela A Carpentier; D'Anne S Duncan; Stephen D Miller
Journal:  Brain Behav Immun       Date:  2007-10-24       Impact factor: 7.217

8.  Inactivation of JNK1 enhances innate IL-10 production and dampens autoimmune inflammation in the brain.

Authors:  Elise H Tran; Yasu-Taka Azuma; Manchuan Chen; Claire Weston; Roger J Davis; Richard A Flavell
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-28       Impact factor: 11.205

Review 9.  Toll-like receptors in neurodegeneration.

Authors:  Eitan Okun; Kathleen J Griffioen; Justin D Lathia; Sung-Chun Tang; Mark P Mattson; Thiruma V Arumugam
Journal:  Brain Res Rev       Date:  2008-09-12

Review 10.  Toll-like receptors expression and signaling in glia cells in neuro-amyloidogenic diseases: towards future therapeutic application.

Authors:  Dorit Trudler; Dorit Farfara; Dan Frenkel
Journal:  Mediators Inflamm       Date:  2010-07-25       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.